- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.02. | Polyrizon: Studie zeigt überlegene nasale Deposition von Naloxon-Formulierung | 1 | Investing.com Deutsch | ||
| 26.02. | Polyrizon Ltd.: Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product | 74 | GlobeNewswire (Europe) | Raanana, Israel, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal administrated solutions... ► Artikel lesen | |
| 26.02. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 10.02. | Polyrizon plant Übernahme im Privatjet-Sektor - Aktie legt zu | 1 | Investing.com Deutsch | ||
| 10.02. | Polyrizon Ltd.: Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator | 156 | GlobeNewswire (Europe) | The Company signed a non-binding MOU agreement with Arrow Aviation, a lucrative high- growth company with annual unaudited revenues of approximately $19 million and approximately $3 million adjusted... ► Artikel lesen | |
| 06.02. | Polyrizon climbs on Clearmind Deal | - | Baystreet.ca | ||
| 06.02. | Polyrizon Partners With Clearmind To Advance Intranasal MEAI For CNS Disorders | 1 | RTTNews | ||
| POLYRIZON Aktie jetzt für 0€ handeln | |||||
| 06.02. | Clearmind und Polyrizon kooperieren bei nasaler MEAI-Formulierung | 1 | Investing.com Deutsch | ||
| 06.02. | Clearmind partners with Polyrizon to develop intranasal MEAI formulation | 1 | Investing.com | ||
| 06.02. | Polyrizon to develop intranasal formulation of Clearmind's MEAI drug | 2 | Investing.com | ||
| 06.02. | Polyrizon entwickelt nasale Formulierung für Clearminds Wirkstoffkandidaten MEAI | 1 | Investing.com Deutsch | ||
| 06.02. | Polyrizon Ltd.: Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation | 198 | GlobeNewswire (Europe) | Collaboration aims to leverage Polyrizon's advanced proprietary intranasal delivery platform to support clinical development of Clearmind's drug candidate proprietary MEAI Raanana, Israel, Feb. 06... ► Artikel lesen | |
| 04.02. | Polyrizon intends to acquire 51% stake in global private aviation company | 2 | Seeking Alpha | ||
| 04.02. | Polyrizon signs MOU to acquire 51% stake in Arrow Aviation | 4 | Investing.com | ||
| 04.02. | Polyrizon Ltd.: Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company | 2 | GlobeNewswire (USA) | ||
| 04.02. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 22.01. | Polyrizon begins usability study for intranasal allergy blocker | 1 | Investing.com | ||
| 22.01. | Polyrizon Ltd.: Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX Allergy Blocker | 1 | GlobeNewswire (USA) | ||
| 22.01. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.01. | Polyrizon Ltd.: Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet | 2 | GlobeNewswire (USA) |
1 2 3 4 Weiter >>
77 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,975 | -6,35 % | PTA-NVR: QIAGEN N.V.: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG | DJ PTA-NVR: QIAGEN N.V.: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG
Gesamtstimmrechte gemäß -- 41 WpHG
QIAGEN N.V.: Veröffentlichung der Gesamtzahl der Stimmrechte nach... ► Artikel lesen | |
| NOVAVAX | 8,382 | -2,38 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 20,010 | 0,00 % | Palatin Technologies, Inc.: Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Advancing differentiated MC4R-based obesity programs into clinical development
Melanocortin-based obesity therapies targeting rare MC4R pathway disorders with... ► Artikel lesen | |
| BIOXXMED | 1,120 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 14.01.2026 | The following instruments on XETRA do have their first trading 14.01.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 14.01.2026
Aktien
1 MHY3130D1013 Heidmar Maritime Hldgs.... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,450 | -3,97 % | Akeso, Inc.: Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM) | Collaboration will evaluate Akeso's cadonilimab in combination with INOVIO's INO-5412 (INO-5401 plus INO-9012) as a potential treatment for glioblastoma (GBM)... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,430 | 0,00 % | COSCIENS Biopharma Inc.: COSCIENS Provides Strategic Update | TORONTO, ONTARIO, March 05, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company") today announced that the Company has made a strategic decision... ► Artikel lesen | |
| XOMA ROYALTY | 22,600 | 0,00 % | XOMA Royalty Corp - 8-K, Current Report | ||
| PHIO PHARMACEUTICALS | 1,160 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update | Treatment Phase for Lead Clinical Candidate PH-762 Dose Escalation Trial is Complete with Favorable Safety, Tolerability and Pathology Data 2025 Financings and Warrant Exercises Strengthen Balance... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| ORAGENICS | 0,923 | +4,85 % | Oragenics, Inc.: Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy | Outlines clinical and growth catalysts for ONP-002 in concussion and mild traumatic brain injury (mTBI) Fully prepared to initiate near-term clinical site onboarding and first patient dosing in Australia... ► Artikel lesen | |
| TENAX THERAPEUTICS | 9,050 | -4,74 % | XFRA NEW INSTRUMENTS AVAILABLE ON 10.02.2026 | The following instruments on XETRA do have their first trading 10.02.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 10.02.2026
Aktien
1 CNE100006V73 Auntea Jenny (Shanghai)... ► Artikel lesen | |
| UNITY BIOTECHNOLOGY | 0,030 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM XETRA - 10.10.2025 | The following instruments on XETRA do have their last trading day on 10.10.2025Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 10.10.2025ISIN NameDE000DB9U2Y9 DT.BANK IS. 20/25US44891CBN20... ► Artikel lesen | |
| EDESA BIOTECH | 5,150 | -8,85 % | Edesa Biotech, Inc.: Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study | Results in a population of 278 patients affirm statistically significant mortality reductionsBenefits observed across severity groups and in subjects with serious comorbiditiesCompany files provisional... ► Artikel lesen | |
| SERES THERAPEUTICS | 7,700 | -2,65 % | Seres Therapeutics, Inc.: Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates | Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience Seres is implementing a focused corporate strategy to advance live biotherapeutic programs... ► Artikel lesen |
Das Unternehmen POLYRIZON LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 13,150 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYRIZON LTD finden Sie auf Wallstreet Online.